Division of Hematology and Oncology, Department of Medicine, The Warren Alpert Medical School of Brown University and Rhode Island Hospital, Providence, RI, USA.
Leuk Lymphoma. 2012 Dec;53(12):2378-82. doi: 10.3109/10428194.2012.694075. Epub 2012 Jun 13.
Primary effusion lymphoma (PEL) is a rare lymphoma associated with Kaposi sarcoma-associated herpesvirus (KSHV), also known as human herpesvirus 8 (HHV8), and characterized by a malignant body cavity effusion without solid organ or nodal involvement. Prognostic factors in patients with PEL have not been systematically studied. We conducted a literature search for patients with HHV8-positive PEL to identify potential prognostic factors for survival. Our search identified 147 patients, among which 104 patients were HHV8-positive. The median overall survival was 9 months. The median age was 57 years with a male predominance (6:1). Pathologically, 33% of the patients expressed CD20 and 69% expressed CD30. Patients with PEL with > 1 body cavity involved had a median overall survival (OS) of 4 months compared with 18 months in patients with only one cavity involved (p = 0.003). Additionally, in patients with one involved body cavity, pericardial involvement was associated with a longer median OS than pleural followed by peritoneal involvement (40, 27 and 5 months, respectively; p = 0.04). In conclusion, our study suggests that the number and location of body cavities involved are prognostic in patients with PEL.
原发性渗出性淋巴瘤（PEL）是一种罕见的淋巴瘤，与卡波西肉瘤相关疱疹病毒（KSHV）有关，也称为人类疱疹病毒 8 型（HHV8），其特征是恶性体腔积液，无实体器官或淋巴结受累。PEL 患者的预后因素尚未系统研究。我们对 HHV8 阳性 PEL 患者进行了文献检索，以确定生存的潜在预后因素。我们的检索确定了 147 名患者，其中 104 名患者为 HHV8 阳性。中位总生存期为 9 个月。中位年龄为 57 岁，男性居多（6:1）。病理上，33%的患者表达 CD20，69%的患者表达 CD30。与只有一个体腔受累的患者相比，有> 1 个体腔受累的 PEL 患者的中位总生存期（OS）为 4 个月，而只有一个体腔受累的患者为 18 个月（p = 0.003）。此外，在一个受累体腔的患者中，与胸腔受累相比，心包受累与更长的中位 OS 相关，随后是腹腔受累（分别为 40、27 和 5 个月；p = 0.04）。总之，我们的研究表明，受累体腔的数量和位置是 PEL 患者的预后因素。
